Estradiol tablets (Julina) are suitable for alternative treatment of symptoms related to estrogen deficiency. The medication for special populations needs to be adjusted according to pregnancy status, liver and kidney function, and other individualized factors to ensure safe and effective treatment.

Applicable Population

1. Postmenopausal women

Used to alleviate vasomotor symptoms, reproductive and urinary tract atrophy, and prevent osteoporosis. Individualized medication should be administered after assessing cardiovascular risk.

2. Patients with premature ovarian failure

Continuous medication is required until the average menopausal age to maintain secondary sexual characteristics and bone health. Suggest combining progesterone to protect the endometrium.

3. Artificial menopausal women

Medication should be started 2-4 weeks after surgery to improve the symptoms of low estrogen caused by surgery. Need to monitor the risk of thrombosis formation.

Medication for special populations

1. Pregnancy period

Disabled. May interfere with fetal development and increase the risk of congenital malformations. Before medication, it is necessary to confirm a negative pregnancy test.

2. Lactation period

Avoid using. Estradiol can enter breast milk, which may inhibit lactation and affect infant sexual development. Suspend breastfeeding when necessary.

3. Liver dysfunction

Use with caution. Severely injured individuals are prohibited from using it. May increase the metabolic burden on the liver, requiring reduction and regular monitoring of transaminases.

4. Renal insufficiency

No need to adjust the dosage. However, patients with end-stage renal disease should be cautious, because water and sodium retention may be increased.

5. Individuals at high risk of thrombosis

Use with caution. Patients with obesity, long-term bed rest, etc. need to be evaluated for their benefit risk ratio. Monitor coagulation function during medication.

6. History of breast cancer

Taboo. The use of estrogen in patients with estrogen dependent tumors may increase the risk of recurrence. Non hormonal replacement options are required.